Multi Cytogenetic Changes in a Patient as Co-Existing MDS and CLL Progresses

Xiangxin Li
Jiale Ma
Luqun Wang
Shuxin Yan
Fanglin Li
Lingling Wang
Lin Wang
Guosheng Li
Daxin Ma
Hao Li

Department of Hematology, Qilu Hospital, Cheoloo College of Medicine, Shandong University, Jinan, Shandong, People’s Republic of China

Background: Chronic lymphocytic leukemia (CLL) and myelodysplastic syndrome (MDS) existing simultaneously in untreated patients is extremely rare. There have only been nine cases of untreated CLL concurrent with or followed by the development of MDS. Of all nine cases, four patients exhibited results of cytogenetic phenotypes all showing more than one abnormal chromosome karyotype. It is unknown whether or not these abnormal chromosome karyotypes change during the development of the disease. Meanwhile, the optimal treatment for the concurrence of CLL with MDS has yet to be identified.

Case Presentation: A 59-year-old Chinese man diagnosed with co-existing CLL with MDS was observed from diagnosis, treatment, relapse to death during an admission period of a total of 158 days. Since being diagnosed with CLL and MDS, he was treated by decitabine and his condition went into remission for three months. Four laboratory tests showed an abnormal chromosome cytogenetic karyotype successively changed during the progression of the disease.

Conclusion: It is the first time the abnormal chromosome karyotype variation significantly associated with the change of the illness was discovered. In the relapse and deterioration stages of the disease, there was t(9;22)(q24; q11.2); add(11)(p15) and other chromosome translocation. Repeated occurrence of TET2 mutation is special at this stage of the disease. Furthermore, decitabine could be beneficial for the treatment of the disease.

Keywords: chronic lymphocytic leukemia, myelodysplastic syndrome, chromosome karyotype, treatment, variation

Background

Chronic lymphocytic leukemia (CLL) is the proliferation of small B-lymphocytes in bone marrow, blood and lymph nodes. In almost all cases where CLL exist simultaneously with myelodysplastic syndrome (MDS), the condition occurred in patients with CLL after treatment with chemotherapy or radiotherapy. The concurrence of CLL with MDS is very rare (Table 1). Given the paucity of molecular information involving mutation genes in the process of two simultaneous malignant phenomena, the mechanism as how it occurs is unclear. The optimal treatment for the concurrence of CLL with MDS has yet to be identified, and the survival time is very poor. Here we report a case of a patient diagnosed with CLL and MDS. He was successfully treated by decitabine and his condition went into remission for 3 months. We found changes involving chromosomal abnormalities during the course of his disease progression. The characteristics of this patient during the process is shown in Table 2.
Case Presentation

On 24 December 2015, a 69-year-old Chinese man with three months’ history of fatigue, dyspnea, heart palpitations after activities presented himself at the hospital. He had no fever, but reported weight loss. His past medical history was significant for hypertension for 20 years and diabetes for 7 years, with blood pressure stabilized at 150/90 mmHg and blood glucose controlled in the normal range. He has no history of a previously known hematologic disease or long-term history of exposure to chemical or radioactive substances. During a physical examination, the following conditions were discovered: lymph node enlargement with a size of 1–3 cm, mild hepatomegaly (3 cm below the costal margin) and moderate splenomegaly (5 cm below the costal margin) with sternal tenderness. Other observations included: normal B-type natriuretic peptide, coagulation, hepatic and renal function, with nothing particularly remarkable about the physical examination to report.

Initial peripheral complete blood cell count (CBC) examination demonstrated hemoglobin (HGB) (7.3 g/L), white blood cell count (WBC) (65.4x10^9/L), neutrophil (NEU) (2.01x10^9/L), lymphocyte (LYM) (63.12x10^9/L), and platelet (PLT) (36x10^9/L) (Figure 1).

The initial laboratory tests (taken for the first time from 25 December 2015 to 13 January 2016) found the following information:

1. The bone marrow (BM) aspirate smears showed a significant increase of hypercellular marrow, 87% of which are mature lymphocytes. Background trilineage hematopoiesis was reduced with normal morphology (Figure 2A).

2. Pathological examination of BM biopsy showed extreme hypercellularity with hematopoietic area at 90%. Abnormal cells containing a large cell body, a moderate amount of cytoplasm, round or oval nucleus increased in number. Nuclear staining region was crude, partially visible nucleoli were observed. Granulocytes, erythrocytes, and megakaryocytes were normal in number (Figure 2E).

3. Flow cytometry analysis of the BM aspirate cells showed (antibodies come from BECKMAN COULTER; BD; Test instrument came from BC. NAVIOS) that the population of mature lymphocytes reviewed represented approximately 75.05% of the nucleated cells, with abnormal cells at 72.29%. The abnormal cells tested positive for CD19, CD23, CD43, Lambda;dim for CD5, CD76, CD81, CD22, SlgD, SlgM, CD38, CD20; and were negative for CD10, FMC7, CD11c, CD103, and Kappa (See attachment file 1–1 for flow cytometry). Matutes/Catovsky score=4 (SmIg dim+, CD5+, CD23+, FMC7-).

4. Cytogenetic test found in chromosome and multi-color fluorescent in situ hybridization (mFISH) analyses showed no changes in 11q22.3,13q14.13,14.13,17p13.1 and+12, while long time 72–96 hours stimulated cultures with CpG-OPN+IL-2(LTSC) of bone marrow showed:66–68, XY,+Y,+1,+2,+3,+4,+6,+6, +7,+8,+9,+11,+12,+13,+15,+16,+17,+21,+21,+21 [ep10]/46, XY[3] (Figure 3A).

<table>
<thead>
<tr>
<th>Subjects</th>
<th>Age</th>
<th>Sex</th>
<th>Karyotype</th>
<th>Classification</th>
<th>OS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bracey AW et al† 1989</td>
<td>72</td>
<td>M</td>
<td>t(1;7),7,+8</td>
<td>MDS-RAEB to AML</td>
<td>5 month</td>
</tr>
<tr>
<td>Sylvester LS et al† 1997</td>
<td>85</td>
<td>M</td>
<td>del(13)(q12q22),+12</td>
<td>MDS-RA</td>
<td>N/A</td>
</tr>
<tr>
<td>Lai et al§ 1999</td>
<td>67</td>
<td>M</td>
<td>Myeloid cells,13q-; Lymphoid cells,+12</td>
<td>MDS-RAS</td>
<td>N/A</td>
</tr>
<tr>
<td>Hana A et al§ 2004</td>
<td>63</td>
<td>M</td>
<td>+12, del(14)(q21)[1]/47, XY,+8[1]/46, XY[23].</td>
<td>MDS-RCMD</td>
<td>7 month</td>
</tr>
<tr>
<td>Luca et al§ 2011</td>
<td>83</td>
<td>M</td>
<td>N/A</td>
<td>MDS/MPN</td>
<td>N/A</td>
</tr>
<tr>
<td>Tambaro F et al§ 2016</td>
<td>N/A</td>
<td>M</td>
<td>N/A</td>
<td>MDS</td>
<td>N/A</td>
</tr>
</tbody>
</table>
### Table 2 Patient Characteristics During the Process

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Peripheral blood analysis</td>
<td>WBC(6.54 x 10^9/L), NEU (2.01 x 10^9/L), LYM (63.12 x 10^3/L), HGB (7.3g/L), PLT (36 x 10^9/L)</td>
<td>WBC(0.89 x 10^9/L), NEU (0.18 x 10^9/L), LYM (0.66 x 10^9/L), HGB (6.2g/L), and PLT (6 x 10^9/L)</td>
<td>WBC(3.69 x 10^9/L), NEU (2.06 x 10^9/L), LYM (1.24 x 10^9/L), HGB (8.0g/L), and PLT (174 x 10^9/L)</td>
<td>WBC(0.69 x 10^9/L), NEU (0.03 x 10^9/L), LYM (0.06 x 10^9/L), HGB (7.7g/L), and PLT (23 x 10^9/L).</td>
</tr>
<tr>
<td>Bone marrow aspiration</td>
<td>Hematopoietic hyperplasia; Mature lymphocytes at 87%; Background trilineage hematopoiesis was reduced with normal morphology.</td>
<td>Hematopoietic hyperplasia; Mature lymphocytes at 21%. Sideroblasts were 35% of all normoblasts. Erythroid series revealed numerous proerythroblast and basophilic erythroblast (56%), with abnormal nucleus easily observed (&lt;10%). Myeloid and megakaryocyte were reduced.</td>
<td>Hematopoietic hyperplasia; Mature lymphocytes at 15%. Sideroblasts were 10% of all normoblasts. erythrocytes were active. Parts of erythroblasts were megaloblastic (&lt;10%). Myeloid hyperplasia was reduced.</td>
<td>Hematopoietic hyperplasia, a large increase in immature cells with megakaryocyte morphology. Blast cells were poorly differentiated, PAS (+). MPO (-). Granulocyte, erythrocyte, and lymphocyte series were significantly reduced.</td>
</tr>
<tr>
<td>Bone marrow biopsy</td>
<td>Hematopoietic area at 90%. Abnormal cells increased in number, containing a large cell body, a moderate amount of cytoplasm, round or oval nucleus. MF-1 level.</td>
<td>Hematopoietic area at 90%. A marked increase in granulocyte and immature erythroid cell and small megakaryocytes. IHC showed CD42b megakaryocytes (+); CD34 (+); CD117, CD5, MPO, CD20 and CD23 (scattered or clustered +). MF-1 level.</td>
<td>Remarkable fibrous proliferation (MF-2 level). Small megakaryocytes were easy to see. IHC revealed the number of abnormal B cells increased, positive for CD20, CD5, CD23, CD42b megakaryocytes (+); CD34 (&lt;2%); CD117 (a small amount); MPO (a small amount); CD34 (-).</td>
<td>Hematopoietic area at 80%. A significant increase in the amount of large body cells with abundant cytoplasm, round or slightly irregular nucleus, thicker nuclear chromatin, and prominent nucleioli, IHC showed negative for CD20, PAX5, CD3, CD138, CD17, CD42b, Ckpd, Cam5.2. Small lymphocytes increased in number and were positive for CD20, PAX5, CD5 and CD23.</td>
</tr>
<tr>
<td>Flow cytometry</td>
<td>Lymphocytes represented 75.05% of the nucleated cells, with abnormal small B lymphocytes at 72.29%, positive for CD19, CD23, CD43, Lambda; dim for CD5, CD76, CD81, CD22, S IgD, S IgM, CD38, CD20; and negative for CD10, FMC7, CD11c, CD103, and Kappa.</td>
<td>Lymphocytes taking up 18.46% of all nucleated cells, with abnormal mature small B lymphocytes at 82.25%, positive for CD19, CD20 (a small amount), CD22, CD23, Lambda, and negative for CD10, FMC7, CD34 and Kappa.</td>
<td>Lymphocytes accounting for 16.2% of all nucleated cells, with abnormal mature small B lymphocytes at 26.06%, positive for CD19, CD23, Lambda but negative for CD5, CD10 and Kappa. A marked increase in the quantity of immature erythrocytes (64.08% of nucleated cells), positive for CD235a, CD36 and CD71, negative for CD34.</td>
<td>Lymphocytes taking up 62.71% of all nucleated cells, with abnormal small mature B lymphocyte at 53.22%, positive for CD19, CD20 (a small amount), CD22, CD23, Lambda, and negative for CD10, FMC7, CD34 and Kappa with light chain restriction. Juvenile erythrocyte and granulocyte had reduced.</td>
</tr>
</tbody>
</table>

(Continued)
Table 2 (Continued).

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Cytogenetics</td>
<td>66-68, XY,+Y,+1,+2,+3,+3, +4,+6,+6,+7, +8,+9, +11,+12, +13,+15, +16,+17,+21, +21, +21[cp10]/46, XY[3]</td>
<td>46, XY[8]</td>
<td>55-65, XY,+Y,+1,+2,+2,+4, +5,+5,+5,+8, t(9;22)(q24; q11.2),+13,+14,+14,+15,+16, +17, +20,+21,+der(22)(q9;22) [cp14]/46, XY[6]</td>
<td>57-59, XY,+Y,+1,+2,+3,+6,+6, +8, add(11)(p15),+13,+15,+16, +19,+21,+21, +21[cp20].</td>
</tr>
</tbody>
</table>

These results were considered consistent with CLL, and MDS was just suspected. Treatment of the patient was initiated with FCR (fludarabine: 25 mg/m² on days 2–4, cyclophosphamide: 250 mg/m² on days 2–4 and rituximab: 375 mg/m² on day 1) on 28 December 2015 for one cycle. However, the patient’s symptoms did not improve and his complete peripheral blood counts decreased day by day. On 9 January,2016, two weeks after diagnosis of CLL, the CBC showed HGB (6.2 g/L), WBC (0.89x 10⁹/L), NEU (0.18x 10⁹/L), LYM (0.66x 10⁹/L), and PLT (6x 10⁹/L) (Figure 1).

A subsequent laboratory test (taken on 16 February 2016 through to 31 March 2016) was performed and the following information was obtained:

1. The subsequent BM aspirate smears demonstrated hematopoietic hyperplasia with mature lymphocytes at 21%. The extracellular staining was positive, and sideroblasts were 35% of all normoblasts. The presence of trilineage hematopoiesis showed that myeloid and megakaryocyte hyperplasia has reduced, but erythrocytes were active. Of note, the erythroid series revealed numerous proerythroblast and basophilic erythroblast (56%), with abnormal nucleus easily observed (<10%) (Figure 2B).

2. Pathological examination of BM biopsy showed a hypercellular (about 90% cellularity) bone marrow with a marked increase in granulocyte and immature erythroid cells, while megakaryocytes remained the same in number. Immunohistochemistry tests showed positive expression for CD42b megakaryocytes, CD34, scattered or clustered positive expression for CD117, CD5, MPO, CD20 and CD23 (Figure 2F).

Figure 1 Tendency of peripheral blood cells during hospitalization and treatment.
3. Flow cytometric immunophenotypic analysis showed a hypercellular (about 87.29% cellularity) bone marrow with lymphocytes taking up 18.46% of all nucleated cells phenotype. It also showed the population of mature small B lymphocyte grew, representing approximately 8.25% of the nucleated cells, positive for CD19, CD20 (a small amount), CD22, CD23, Lambda, and negative for CD10, FMC7, CD34 and Kappa, with light chain restriction (See attachment file 1–2 for flow cytometry).

4. A gene rearrangement examination demonstrated that IgH and IgK gene rearrangement were positive, while TCRβ, TCRγ were negative. Other common leukemia fusion genes were negative. A second-generation gene sequencing was conducted at the same time with TET2 mutation (62.68%, exon3: c. G652A: p.V218M rs 6,843,141), which commonly appears in Chronic myelomonocytic leukemia (CMML).

5. Conventional cytogenetic analysis of chromosome karyotypes of bone marrow with unstimulated short time culture (USSTC) showed 46, XY[8] (Figure 3B).

Considering all above laboratory results, as well as the inefficiency of the FCR regimen in the recovery of marrow dyserythropoiesis especially of erythroid and megakaryocytic lines, the patient suffering from CLL with MDS-multilineage dysplasia (MLD) was newly diagnosed. We thereby deactivated the above drugs, and turned to decitabine for the patient’s treatment. During admission from 17 February 2016 on which cycle 1 of FCR was administered, through to Day 60–9 April 2016, he received decitabine treatment (20 mg/m2/day for 5 days every 28
days) for two cycles. His clinical symptoms, as well as peripheral CBC test improved and a very good clinical outlook was achieved. His condition went into remission for three months. On 10 May 2016, 83 days after the diagnosis of CLL concurrent with MDS, laboratory testing showed HGB (8.0 g/L), WBC (3.69x 10^9/L), NEU (2.06x 10^9/L), LYM (1.24x 10^9/L) and PLT (174x 10^9/L) (Figure 1).

A subsequent laboratory test was performed for the third time over the period of 11 May 2016 to 22 May 2016, the following was observed:

1. The BM aspirate smears demonstrated hematopoietic hyperplasia with mature lymphocytes accounted for 15% of cells present. Sideroblasts were 10% of all normoblasts. The presence of trilineage hemopoiesis showed that myeloid hyperplasia had reduced, but erythrocytes were active. Parts of erythroblasts were megaloblastic. Megakaryocyte was normal. Of note, some unknown cells with a large body that are poorly differentiated take up 12% of the nucleated cells, reacting positive for PAS, but negative for MPO, the morphology of which was highly suspected as that of small megakaryocytes (Figure 2C).

2. The pathological test of BM biopsy showed granulocyte, erythrocyte, and megakaryocyte cells were easily observed. Lymphocytes were focally or

---

**Figure 1** BM aspirate smears showing hematopoietic hyperplasia with mature lymphocytes accounted for 15% of cells present. Sideroblasts were 10% of all normoblasts. The presence of trilineage hemopoiesis showed that myeloid hyperplasia had reduced, but erythrocytes were active. Parts of erythroblasts were megaloblastic. Megakaryocyte was normal. Of note, some unknown cells with a large body that are poorly differentiated take up 12% of the nucleated cells, reacting positive for PAS, but negative for MPO, the morphology of which was highly suspected as that of small megakaryocytes (Figure 2C).
dispersely distributed. Immunohistochemistry testing revealed the number of abnormal B cells increased, which were positive for CD20, CD5, CD23, and 42b megakaryocytes, CD34 (>2%), CD117 (a small amount), MPO (a small amount), but negative for CD3 (Figure 2G).

3. Flow cytometric immunophenotypic analysis showed a hypercellular (about 80.06% cellularity) bone marrow with lymphocytes accounting for 16.2% of all nucleated cell phenotypes. It also showed an increase in the population of abnormal mature small B lymphocyte phenotype, representing approximately 26.06% of the nucleated cells, positive for CD19, CD23, Lambda but lack CD5, CD10 and Kappa, and light chain was expressed restrictively. Additionally, there was a marked increase in the quantity of immature erythrocytes (64.08% of nucleated cells), which were positive for CD235a, CD36 and CD71 but lack CD34 positive progenitor cells. (See attachment file 1–3 for flow cytometry).

4. The subsequent cytogenetic karyotypes examination with LTSC of bone marrow showed two clones: 55–65, XY,+Y,+1,+2,+2,+4,+5,+5,+5,+8, t(9;22) (q24;q11.2),+13,+14,+14,+15,+16,+17,+20,+21, +der(22)t(9;22) [p14]/46, XY[6] (Figure 3C).

5. A second-generation gene sequencing was conducted for the second time with TET2 mutation (52.86%, exon3: c.G652A: p.V218M rs 6,843,141).

These results indicated the patient was still suffering from CLL with MDS-MLD. After three months of remission, on 13 May 2016, during the third cycle of chemotherapy, decitabine (20 mg/m2/day for 5 days) combined with cytarabine (0.02g/d d3-9) was given to the patient. Repetitive laboratory observations showed that peripheral blood CBC appeared to have the tendency of looking like a “drop-return-drop-return” model with some symptomatic and supportive measures. Three weeks following the treatment, the patient’s leukocyte gradually increased, while the number of platelets decreased. Based on the performance score system of the Eastern Cooperative Oncology Group (ECOG), the patient’s condition was deteriorating. The next course of treatment for the patient was decitabine combined with chlorambucil. However, the patient’s condition failed to significantly improved. He was better for a while and then had a relapse.

The fourth laboratory tests taken on 13 June 2016 through to 29 June 2016 documented the following results:

1. BM aspirate smears showed a hypercellular bone marrow with a large increase in immature cells with megakaryocyte morphology. These blast cells were poorly differentiated, reacting strongly positive for PAS, but negative for MPO. Granulocyte, erythrocyte, and lymphocyte series were significantly reduced (Figure 2D).

2. Pathological examination of BM biopsy showed a hypercellular (about 80% cellularity) bone marrow with a significant increase in the amount of large body cells with abundant cytoplasm, round or slightly irregular nucleus, thicker nuclear chromatin, and prominent nucleoli, none of which contains antibodies including CD20, PAX5, CD3, CD138, CD117, CD42b, Ckpan, Cam5.2 for B cells, T cells, plasma cells, myeloid precursor cells, and megakaryocytes cells. Small lymphocyte cells increased in number, and were positive for CD20, PAX5, CD5 and CD23. Granulocyte, erythrocyte, and megakaryocyte cells were easily observed (Figure 2H).

3. Flow cytometric immunophenotypic analysis showed a hypercellular (about 52.49% cellularity) bone marrow with lymphocytes taking up to 62.71% of all nucleated cells phenotype. It also showed an increase in the population of abnormal small mature B lymphocyte phenotype representing approximately 53.22% of lymphocyte, which showed up positive for CD19, CD20 (a small amount), CD22, CD23, Lambda, and negative for CD10, FMC7, CD34 and Kappa with light chain restriction. Juvenile erythrocyte and granulocyte had reduced. (See attachment file 1–4 for flow cytometry).

4. The fourth cytogenetic karyotype examination with LTSC of bone marrow showed one clone: 57–59, XY,+Y,+1,+2,+3,+6,+8, add(11)(p15),+13,+15,+16, +19,+21,+21[2p20] (Figure 3D).

These results showed the patient was still affected with CLL. However, the increased abnormally large cells belonged to an unknown series.
Unfortunately, the patient developed pneumonia. On 2 July 2016 he died of uncontrolled pulmonary infection. He survived a total of 138 days after his diagnosis.

As the patient’s condition progresses, abnormal chromosome karyotype variations significantly associated with the change of the illness were discovered. In the relapse and deterioration stages of the disease, gene translocation as t(9;22)(q24; q11.2), add(11)(p15) and repeated occurrence of TET2 mutation (exon3: c.G652A: p.V218M rs 6,843,141) were successively found.

Discussion

Complex karyotype (CK), defined by the presence of 3 or more chromosome aberrations, represents a prognostic negative biomarker associated with an inferior outcome independent of the International Prognostic Index for patients with CLL (CLL-IPI), and a worse response to treatment including novel agents such as BCL2 inhibitor venetoclax. Although CK is detectable in 14–34% of untreated CLL patients, it seldom brings about abnormal bone marrow morphologic changes like MDS or AML, especially simultaneously in untreated CLL.

As reported, the most frequent chromosome breakpoints in CLL are 13q, followed by 14q, 18q, 17q, and 17p; notably there exists a wide spectrum of translocation partners with 13q. In CK cases, besides co-existing trisomies of chromosomes 12/18/19 (2.4% in multiple trisomies), which indicates a more favorable clinicobiological feature. Other CK especially those with five or more cytogenetic aberrations follow a particularly aggressive clinical course. We reviewed the clinical, immunophenotypic and cytogenetic features of the nine cases of untreated CLL concurrent with MDS reported. Of all nine MDS patients, four cases recorded the presence of cytogenetic abnormalities: t(1;7),-7,+8; del(13)(q12q22), +12; Myeloid cells,13q- and lymphoid cells, +12; and +12, del(14) (q21)[1]/47, XY,+8[1]/46, XY[23].

In the study of Tambaro FP, the outcomes of CLL diagnosed with AL (n=38) or MDS (n=57), either concurrently (n=5) or subsequently (n=90) were documented, only two of which were concurrently diagnosed with CLL and MDS. The chromosome on metaphase karyotype involved in AML or MDS with CLL are 5,7,8,11 and 17.

Karyotype for MDS and AL was poor, 63% and 68% respectively according to the International Prognostic Scoring System (IPSS) of WHO 2016. 8% of AL patients and 28% of MDS patients received treatments using demethylating agents such as azacitidine or decitabine. In this case, the subject was found to have abnormal chromosomes that are involved with almost all chromosomes, and for the first time we found the abnormal chromosome karyotypes variation significantly associated with the change of the illness. In the severe deterioration stage of the disease, a gene translocation t(9;22)(q24; q11.2) was shown. The significance of t(9;22) had not been reported in CLL, and is also a very rare event in MDS. Manish Kumar Singh reported two cases of De novo Philadelphia chromosome positive myelo-dysplastic syndrome. In literature, 40 cases of Ph+MDS were recorded, of which less than half showed positive Ph at initial diagnosis. The presence of the Philadelphia chromosome probably indicates a poor prognostic group of MDS. This point is consistent with the temporary effect of decitabine in the process.

More than two genes were identified to have undergone alterations including gene deletion and point mutation in clinical samples of CLL/MDS patients, suggesting that multiple gene mutations are required for leukemogenesis, such as ASXL1 and SETBP1 or N-Ras in MDS etiology. In this case, no other gene mutation occurred while TET2 mutation was repeatedly found as the second-generation gene sequencing was conducted twice. TET2 is a major factor in hematopoietic function. Some hematologic malignancies such as myelodysplastic syndrome, acute myelogenous leukemia or chronic myelogenous leukemia are associated with TET2 mutations. Maria HS observed that TET2 was overexpressed in CLL cells compared with healthy donor cells. In terms of prognosis, TET2 and IDH1 were observed to be associated with longer TFS than those with low expression. We therefore hypothesised that TET2 mutation in this patient mainly acted on the proliferation of MDS clones, but had little effect on the maintenance of CLL malignant clones. The temporary efficacy of demethylation drug may also support the diagnosis of MDS rather than CLL co-existing with CK.

Furthermore, it is unknown whether these abnormal genes were involved in the whole process of the disease simultaneously or successively. Or did they drift from initially altered genes to other newly changed genes as the disease develops. From observing the patient’s progress, we first noticed that multiple chromosomal karyotype mutations one after another are involved in the deterioration process of the disease as the condition of the patient with co-existing MDS and CLL progresses. This observation indicates cell genetic karyotype monitoring is very important in the treatment of leukemia. The
findings will be beneficial in proving the pathogenesis of leukemia in the future.

**Conclusion**

Complex karyotype (CK) as a negative biomarker is detectable in CLL, while it seldom brings about abnormal bone marrow morphologic changes like MDS or AML, especially simultaneously in untreated CLL. In this study, a patient who was simultaneously suffering from CLL and MDS was observed. His condition failed to go into remission after treatment with the FCR regimen, while it went into remission for three months after using decitabine, which supports the diagnosis of CLL co-existing with MDS. An abnormal chromosome karyotype successively changed during the progression of the disease. This novel case is the first time abnormal chromosome karyotype variation significantly associated with the change of the illness was discovered. The relapse and deterioration stages of the disease involved gene transplantation as t(9;22)(q24; q11.2) and add(11)(p15), and repetition of TET2 mutation (exon3: c.G652A: p.V218M rs 6,843,141). Monitoring the bone marrow morphological changes and abnormal chromosome karyotype variation had some guiding effect on our choice of medication. The collection of this information will benefit etiological research in the future.

**Abbreviations**

CLL, chronic lymphocytic leukemia; MDS, myelodysplastic syndrome; CBC, complete blood cell count; HGB, hemoglobin; WBC, white blood cell; NEU, neutrophil; LYM, lymphocyte; PLT, platelet; BM, bone marrow; RA, refractory anemia; RAS, refractory anemia with sideroblasts; RAEB, refractory anemia with excess blasts; CMML, chronic myelomonocytic leukemia; RCMD, refractory cytopenia with multiple dysplasias; MDS-MLD, MDS with multilineage dysplasia; ECOG, Eastern Cooperative Oncology Group.

**Data Sharing Statement**

All data generated or analyzed during this study are included in this published article.

**Ethics Approval and Consent**

This study was approved by the Ethics Committee of the Qilu Hospital, Cheelu College of Medicine, Shandong University. An informed consent form was signed by the son of the patient to publish the case details.

**Consent to Publication**

Written informed consent was obtained from the son of the patient for publication of this case report and accompanying images.

**Acknowledgments**

We thank the Laboratory of the Blood Institute of China Academy of Medical Sciences (Tianjin, China) who assisted us in performing the FISH and cytogenetic analysis.

**Funding**

This work was supported by The Key Research and Development Program of Shandong Province (No. 2017GSF18133, No. 2016GSF201038). Those providing funds had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**